Moderna shares tank after FDA delays COVID vaccine for 12- to 17-year-olds

Moderna shares tank after FDA delays COVID vaccine for 12- to 17-year-olds


Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.